NCT02605421
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
At risk: Primary completion moved 12 months later.
See at-risk trials from Masonic Cancer Center, University of Minnesota
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 16 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2027
- Eligibility criteria shortened, about 27 words
- Study completion pushed from Dec 2026 to Dec 2028
- Secondary endpoints: details revised at 2 of 3 entries
- Notable Primary completion date: Oct 1, 2025 to Oct 1, 2026
- Study completion date: Dec 2025 to Dec 2026
- Notable Primary completion date: Jul 2024 to Oct 1, 2025
- Study completion date: Jul 2025 to Dec 2025
- Notable Primary completion date: Jul 2023 to Jul 2024
- Study completion date: Jul 2023 to Jul 2025
- Notable Primary completion date: Jul 2022 to Jul 2023v16
Show 10 earlier versionsHide 10 earlier versions
- Notable Primary completion date: Jul 2021 to Jul 2022v15
- Minor Site contact updatedv14
- Notable Primary completion date: Jul 2020 to Jul 2021v13
- Minor Primary completion date: Jan 2020 to Jul 2020
- Study completion date: Jan 2023 to Jul 2023
- Notable Eligibility criteria revisedv11
- Notable Eligibility criteria expanded, about 67 wordsv9
- Minor Site contact updatedv5
- Minor Site contact updatedv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Jan 2016 to Jun 2016
- Primary endpoint revised
- Secondary endpoints revised (3)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
Drugs: Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin
Biologicals: Autologous Stem Cell Infusion, Granulocyte colony stimulating factor
Sites
1 site in 1 country
- Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota, United States